Acquisition, Persistence, and Clearance of Human Papillomavirus Infection Among Male Virgins Residing in Brazil, Mexico, and the United States
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
LIU, Zhiyue
NYITRAY, Alan G.
HWANG, Lu-Yu
SWARTZ, Michael D.
ABRAHAMSEN, Martha
LAZCANO-PONCE, Eduardo
GIULIANO, Anna R.
Citação
JOURNAL OF INFECTIOUS DISEASES, v.217, n.5, p.767-776, 2018
Resumo
Background. Little is known about the natural history of human papillomavirus (HPV) infection in male virgins. This study estimated the incidence and clearance of genital HPV infection and the factors associated with these measures among men who denied at baseline ever having penetrative sex. Methods. A cohort of 4123 men residing in Brazil, Mexico, and the United States were followed every 6 months for up to 10 visits. Genital exfoliated cells were collected and genotyped for 36 HPV types. Eighty-seven men were classified as virgins and included for analysis. Cox proportional hazards models identified factors associated with the incidence and clearance of genital HPV infection. Results. The incidence rates for any HPV infection among virgins who did and those who did not initiate sex during follow-up were 26.2 and 14.6 cases/1000 person-months, respectively. After penetrative sex initiation, 45.5% of men acquired HPV within 24 months. Younger age, current smoking, no recent female sex partners, and prevalent HPV infection were associated with high-risk HPV clearance. Conclusion. Virgins who did not initiate sex during follow-up still acquired HPV infection, possibly through nonpenetrative sexual contact. Further prospective cohort studies are needed to better understand factors associated with HPV acquisition and clearance in male virgins and recent nonvirgins.
Palavras-chave
Human papillomavirus, male, virgins, incidence, persistence, clearance
Referências
- Chandra Anjani, 2011, Natl Health Stat Report, P1
- Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
- Ghanem KG, 2005, SEX TRANSM INFECT, V81, P421, DOI 10.1136/sti.2004.013193
- Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151
- Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
- Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
- Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
- Houlihan CF, 2016, J ADOLESCENT HEALTH, V58, P295, DOI 10.1016/j.jadohealth.2015.10.248
- [Anonymous], 2012, IARC MON EV CARC R B, V100, P255
- Ingles DJ, 2015, PAPILLOMAVIRUS RES, V1, P126, DOI 10.1016/j.pvr.2015.09.001
- Kissinger P, 1999, AM J EPIDEMIOL, V149, P950
- LAGARDE E, 1995, AM J EPIDEMIOL, V141, P1194, DOI 10.1093/oxfordjournals.aje.a117393
- Liu ZY, 2016, J INFECT DIS, V214, P1188, DOI 10.1093/infdis/jiw353
- Liu ZY, 2016, SEX HEALTH, V13, P10, DOI 10.1071/SH15089
- Lu BB, 2012, CANCER RES, V72, P676, DOI 10.1158/0008-5472.CAN-11-0751
- Lu BB, 2009, J INFECT DIS, V199, P362, DOI 10.1086/596050
- National Institute of Alcohol Abuse and Alcoholism, DRINK LEV DEF
- Oh JK, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-13
- Pamnani SJ, 2016, CANCER RES, V76, P6066, DOI 10.1158/0008-5472.CAN-16-0224
- Schabath MB, 2012, CANCER EPIDEM BIOMAR, V21, P102, DOI 10.1158/1055-9965.EPI-11-0591
- Schuster MA, 1996, AM J PUBLIC HEALTH, V86, P1570, DOI 10.2105/AJPH.86.11.1570
- Shew ML, 2013, J INFECT DIS, V207, P1012, DOI 10.1093/infdis/jis775
- Shrier I, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-70
- SMITH TW, 1992, SOC BIOL, V39, P203
- Winer RL, 2003, AM J EPIDEMIOL, V157, P218, DOI 10.1093/aje/kwf180